CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
MK-3682Bdrug
Likely dose
MK-3682B 225 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02661126
NCT02661126Phase 1Completed
CompareCT.gov

A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682B (MK-3682/MK-5172/MK-8408 Fixed Dose Combination) When Administered to Subjects With Moderate and Severe Renal Insufficiency

Merck Sharp & Dohme LLC·interventional·Posted Jan 22, 2016·Updated Jan 9, 2019

In Brief

A Phase 1 clinical trial evaluating MK-3682B for Hepatitis C. Completed, enrolled 16 participants.

Detailed Summary

The purpose of this study is to compare the plasma pharmacokinetics (PK) of single doses of MK-3682B, a fixed dose combination (FDC) tablet containing uprifosbuvir (MK-3682) + grazoprevir (MK-5172) + ruzasvir (MK-8408) in participants with moderate (Part 1) and severe (Part 2) renal insufficiency (RI) to plasma PK in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 22, 2016
Enrollment StartJan 19, 2016
Primary CompletionAug 26, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.4 years ago

Interventions

MK-3682Bdrug

FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.